Assessment of Nonalcoholic Fatty Liver Disease Progression in Children Using Magnetic Resonance Imaging
- PMID: 30041934
- PMCID: PMC6429948
- DOI: 10.1016/j.jpeds.2018.05.024
Assessment of Nonalcoholic Fatty Liver Disease Progression in Children Using Magnetic Resonance Imaging
Abstract
Objective: To assess liver disease progression using paired magnetic resonance imaging (MRI) measurements of liver fat fraction (FF) and stiffness.
Study design: Retrospective cohort study including patients with nonalcoholic fatty liver disease who had undergone repeat MRI studies. Descriptive statistics were used, as well as Pearson or Spearman correlation when appropriate. Mixed model analyses were used to determine relationships between liver FF/stiffness and predictor variables.
Results: Sixty-five patients (80% non-Hispanic, mean age 14 ± 3 years) were included. Time from first to last MRI was 27 ± 14 months. Over time, body mass index z score remained stable, and there were no significant differences in mean serum aminotransferases, insulin, glucose, triglycerides, low-density lipoprotein, and high-density lipoprotein (HDL) levels. However, the proportion of patients with alanine aminotransferase (ALT) < 50 U/L increased. MRI FF and stiffness decreased in 29% and 20% of patients, respectively, and increased in 25% and 22% of patients, respectively. There was a weak positive correlation between FF change and ALT change (r = 0.41, P = .053) and a moderate negative correlation between change in FF and change in serum HDL levels (r = -0.58, P = .004). After adjusting for HDL, increase in serum insulin was the only variable predictive of increase in FF (P = .061). There was no correlation between change in liver stiffness and change in ALT (r = .02, P = .910).
Conclusions: MRI-determined hepatic FF and stiffness improved in a minority of patients overtime. ALT levels were not reflective of the change in FF or stiffness. MRI-based imaging is complementary in the assessment of NAFLD progression.
Keywords: MR elastography; Proton density fat fraction; hepatic fibrosis liver stiffness; hepatic steatosis; pediatric NAFLD; progression.
Copyright © 2018 Elsevier Inc. All rights reserved.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures
References
-
- Diehl AM, Day C. Cause, pathogenesis, and treatment of nonalcoholicsteatohepatitis. N Engl J Med 2017;377:2063–72. - PubMed
-
- McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol 2015;62:1148–55. - PubMed
-
- Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005;129:113–21. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
